Antibodies to MUC16 and methods of use thereof
AssigneeMemorial Sloan Kettering Cancer Center
InventorsDavid Spriggs, Dharmarao Thapi
Life of this patent
Estimating the term…
Abstract
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.
Claims43
An isolated monoclonal antibody, or an antigen-binding fragment thereof, that specifically binds to a MUC16 polypeptide or to an antigenic portion thereof, wherein the amino acid sequence of the MUC16 polypeptide is CGVLVTTRRRKKEGEYNVQQQ (SEQ ID N0:03).
A chimeric monoclonal antibody comprising (a) human constant regions;
- and (b) the variable regions of an antibody as produced by a hybridoma cell deposited at the ATCC under accession number PTA-11773, or an antigen-binding fragment of said chimeric monoclonal antibody.
A humanized monoclonal antibody comprising (a) human constant regions;
- (b) human framework regions;
- and (c) the complementary determining regions of an antibody as produced by a hybridoma cell deposited at the ATCC under accession number PTA-11773, or an antigen-binding fragment of said humanized monoclonal antibody.
A single chain variable fragment (scFv) comprising a variable heavy (VH) chain and a variable light (VL) chain, wherein the VH chain and the VL chain are of a monoclonal antibody that specifically binds to a MUC16 polypeptide or to an antigenic portion thereof, wherein the amino acid sequence of the MUC16 polypeptide is CGVLVTTRRRKKEGEYNVQQQ (SEQ ID NO:03).
A scFv comprising a VH chain and a VL chain, wherein the VH chain and the VL chain are of an antibody as produced by a hybridoma cell deposited at the ATCC under accession number PTA-11773.
A scFv comprising a VH chain and a VL chain, wherein the VH chain and the VL chain are of an antibody comprising (a) human framework regions;
- and (b) the complementary determining regions of an antibody as produced by a hybridoma cell deposited at the ATCC under accession number PTA-11773.
A hybridoma cell that produces an antibody that specifically binds to a MUC16 polypeptide or to an antigenic portion thereof, wherein the amino acid sequence of the MUC16 polypeptide is CGVLVTTRRRKKEGEYNVQQQ (SEQ ID NO:03).
A method for producing an antibody that specifically binds to a MUC16 polypeptide or to an antigenic portion thereof, comprising administering to a subject an immunologically effective amount of a MUC16 polypeptide, wherein the amino acid sequence of the MUC16 polypeptide is CGVLVTTRRRKKEGEYNVQQQ (SEQ ID NO:03).
Dependencies are inferred from the claim text.